Cingulate Inc (CING)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.10-2.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CING
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CING — officer change
Dated 2026-07-23
Chief Legal Officer — Mr. Nilay Patel: The Chief Legal Officer position was eliminated, resulting in the departure of Mr. Nilay Patel.
Why it matters: A strong cash position helps with operations and growth. This is important for investors.
Supportive ifCingulate has more than $25 million in cash and equivalents in Q2 2026.
Worry ifCingulate has less than $20 million in cash and equivalents in Q2 2026.
Why it matters: Watching cash levels is important. They affect the company's ability to fund operations and growth.
Watch forCash and cash equivalents rise a lot. This is due to new capital raises or funding rounds.
Also watch forCash levels fall quickly. This may mean there are money problems or rising costs to run the business.
Why it matters: Resubmission is key for Cingulate to move forward with its ADHD treatment. Approval could lead to commercialization.
Supportive ifCingulate submits the NDA to the FDA addressing all CMC requests from the Complete Response Letter.
Worry ifCingulate delays the NDA resubmission. This is beyond the expected timeline and lacks good reasons.
Why it matters: Cingulate is getting ready to launch CTx-1301 after it gets approval.
Supportive ifCingulate says it will finish key sales plans by Q3 2026.
Worry ifCingulate reports delays in building sales plans or a sales team.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$258 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $679 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,913 loss on $10,000 · 69.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: FDA feedback will indicate whether the company has addressed the issues raised in the CRL. This is critical for future approval.
Watch forThe FDA gives positive feedback on the resubmitted NDA. It also provides a review timeline.
Also watch forThe FDA sends another CRL or delays the review. This shows there are still unresolved issues.
Why it matters: If revenue growth speeds up, it could signal a positive shift in the company's performance.
Supportive ifCingulate's revenue growth shows an increase back toward 10% year over year.
Worry ifRevenue growth continues to slow or remains below 10% year over year.
Why it matters: The $12 million from private placements is important. It helps keep operations running during losses.
Watch forThe company shows better operational results. This is thanks to using the private placement funds well.
Also watch forThe company still faces operational problems. This is true even with the private placement funds.
Why it matters: Higher losses mean worse financial health. It shows management struggles to control costs.
Worry ifQ2 operating losses are more than $7.9 million.
Less concerning ifOperating losses drop to less than $7.9 million.
Why it matters: Getting ready for commercial sales is important for a product launch if FDA approves CTx-1301.
Supportive ifManagement says they are making good progress in market access and distribution deals by Q4 2026.
Worry ifThere are no new updates on commercial readiness. There are also no delays in distribution deals.
Why it matters: Cingulate's use of the $12 million raised will affect how it manages losses.
Watch forA report shows good use of private placement funds to cut losses.
Also watch forNo clear progress on using private placement funds well.
Why it matters: Resubmitting the NDA is crucial for Cingulate to move forward with CTx-1301. Approval could lead to market entry for their ADHD treatment.
Supportive ifThe NDA for CTx-1301 is resubmitted to the FDA by the end of Q4 2026.
Worry ifThe NDA resubmission is delayed past Q1 2027. Management has not been clear.
Why it matters: Building the IP portfolio is important. It protects CTx-1301 and helps its market position.
Supportive ifCingulate announces more patents granted or pending for CTx-1301 by Q1 2027.
Worry ifNo new patents are granted, or existing patents face challenges that could weaken IP protection.